Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This historical review examines the diagnostic and etiological understanding of alopecia areata, emphasizing the evolution of theories and the impact of immunological data, while providing no new clinical results.

This retrospective study described the demographic characteristics, treatments, and prognosis of children with alopecia areata in a clinical setting, reporting a remission rate of 34.5% and highlighting the need for more comprehensive epidemiological data in this population.

This study found that while alopecia is a less serious manifestation of lupus, it significantly impacts the quality of life due to its psychosocial effects.

Treatments for autoimmune hair loss have limited success and patients need emotional support and self-acceptance.

This study found that low-dose intermittent corticosteroid therapy may be a successful and well-tolerated treatment option for patients with alopecia areata, including those with alopecia totalis and universalis.

This study found that topical cyclosporin-A may lead to moderate recovery in patients with severe or refractory alopecia areata, particularly in focal type cases.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, predominantly pitting, which was significantly linked to longer disease duration but not the severity of scalp hair loss.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, and while this was associated with longer disease duration, it did not correlate with the severity of scalp hair loss.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

In this retrospective study, researchers observed that alopecia areata manifests in various forms among Malagasy children and presents challenges in treatment, with mixed regrowth results following corticosteroid therapy and methotrexate.

This review article discusses recent advances in stem cell-based therapies for Alopecia Areata, noting preliminary clinical trials show significant hair regrowth, but emphasizes the need for thorough evaluation of long-term safety and efficacy.

This case report observed marked hair regrowth in a patient with refractory alopecia areata using a combination of platelet-rich plasma, low-level light therapy, and microneedling alongside topical and oral agents.

This study describes alopecia areata as a long-term, immune-mediated disorder characterized by non-scarring hair loss, often occurring in genetically predisposed individuals and possibly triggered by T-cell-mediated inflammation, environmental stressors, and genetic factors.

This study explains that alopecia areata, a long-term immune-mediated disorder causing patchy baldness, results from an immunological attack on hair follicles, often in genetically predisposed individuals, with a complex mix of immunological, environmental, and genetic factors involved in its development.

This source explores alopecia areata, an immune-mediated disorder causing patchy hair loss due to immunological attacks on hair follicles, with a complex interaction of genetic, environmental, and immunological factors, particularly T-cell-mediated inflammation, contributing to its onset.

In this research, the authors describe alopecia areata as a long-term, immune-mediated disorder that causes non-scarring hair loss due to an immunological attack on hair follicles, often occurring in genetically predisposed individuals and manifesting in childhood or early adulthood.

This abstract explains that alopecia areata is an immune-mediated condition causing non-scarring hair loss, typically in genetically predisposed individuals, with its etiology linked to immune dysregulation, environmental stressors, and genetic factors.

This source describes alopecia areata as a long-term, immune-mediated disorder causing non-scarring hair loss, often starting in childhood or early adulthood due to genetic predisposition and an immunological attack on hair follicles.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This study identified changes in immune activation, ferroptosis, and structural genes in alopecia areata subtypes, suggesting molecular markers that might help understand disease variability and guide future treatments.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

This meta-analysis found that patients with alopecia areata, particularly those with more extensive forms like alopecia totalis and universalis, may face a higher risk of cardiovascular disease, though no links were found with specific conditions like ischemic stroke or myocardial infarction.

This meta-analysis found that patients with alopecia areata, especially those with alopecia totalis or alopecia universalis, have an increased risk of cardiovascular disease, possibly due to shared immunological mechanisms and systemic inflammation. Further research is needed to confirm these findings and explore underlying mechanisms.

This meta-analysis found that patients with alopecia areata, especially those with more severe forms like alopecia totalis or universalis, may have an increased risk of cardiovascular disease, suggesting a potential link between the systemic inflammation in AA and cardiovascular risk.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

This study surveyed German dermatologists about treating children and adolescents with alopecia areata, revealing significant emotional challenges like bullying and low self-esteem, dissatisfaction with available treatments, and a need for both psychological support and new therapeutic guidelines.

This abstract provides background information on alopecia areata, describing it as an autoimmune condition leading to non-scarring, patchy hair loss but does not report specific study results.